12-Jun-2026
Norges Bank Discloses 2.59% Stake in Qiagen
TipRanks (Fri, 12-Jun 5:47 PM ET)
Goldman Sachs disclosed as 2.82% shareholder in Qiagen via AFM filing
TipRanks (Fri, 12-Jun 5:47 PM ET)
Norges Bank Discloses 3.23% Voting Stake in Qiagen
TipRanks (Fri, 12-Jun 5:46 PM ET)
Goldman Sachs reports 2.52% stake in Qiagen via AFM filing
TipRanks (Wed, 10-Jun 5:18 PM ET)
Goldman Sachs Reports 3.24% Indirect Stake in QIAGEN via AFM Filing
TipRanks (Wed, 10-Jun 5:18 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
PRNewswire (Thu, 4-Jun 10:09 AM ET)
Business Wire (Thu, 28-May 4:05 PM ET)
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
Globe Newswire (Thu, 21-May 8:00 PM ET)
Business Wire (Wed, 20-May 4:05 PM ET)
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky
PRNewswire (Wed, 20-May 9:00 AM ET)
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Qiagen N.V. Common Shares trades on the NYSE stock market under the symbol QGEN.
As of June 12, 2026, QGEN stock price declined to $37.06 with 1,783,922 million shares trading.
QGEN has a beta of 0.80, meaning it tends to be less sensitive to market movements. QGEN has a correlation of 0.07 to the broad based SPY ETF.
QGEN has a market cap of $7.63 billion. This is considered a Mid Cap stock.
Last quarter Qiagen N.V. Common Shares reported $492 million in Revenue and $.54 earnings per share. This fell short of revenue expectation by $-7 million and met earnings estimates .
In the last 3 years, QGEN traded as high as $57.82 and as low as $32.53.
The top ETF exchange traded funds that QGEN belongs to (by Net Assets): IWR, IWD, FXH, IWS, PBE.
QGEN has underperformed the market in the last year with a return of -16.4%, while the SPY ETF gained +24.1%. In the last 3 month period, QGEN fell short of the market, returning -9.9%, while SPY returned +11.6%. However, in the most recent 2 weeks QGEN has outperformed the stock market by returning +1.3%, while SPY returned -1.9%.
QGEN support price is $36.70 and resistance is $38.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QGEN shares will trade within this expected range on the day.